Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient

Andrea Boutros, Chiara Schiavi, Federica Cecchi, Francesco Spagnolo, Antonio Guadagno, Enrica Teresa Tanda, Francesca Giusti, Giuseppe Murdaca, Paola Queirolo

Research output: Contribution to journalArticlepeer-review

Abstract

Adjuvant treatment of operated melanoma has deeply changed in the last few years with the introduction of immune-checkpoint inhibitors and BRAF/MEK inhibitors. Sarcoidosis is a systemic inflammatory disease causing non-caseous granulomatous reactions. Sarcoid-like granulomatous reactions have been reported in patients with advanced melanoma, mostly related to immunotherapy with immune-checkpoint inhibitors. We report a case of a 38-year-old woman with stage III operated melanoma treated with adjuvant BRAF plus MEK inhibitors, who developed sarcoidosis-like syndrome with systemic involvement, resolved after discontinuation of treatment. The occurrence of immune-related toxicity with the use of MAPK inhibitors supports the hypothesis that this class of drugs may also have an immunological effect, and that the long-term efficacy of adjuvant MAPK inhibitors may be due to their immunological function.

Original languageEnglish
Pages (from-to)579523
JournalFront. Immunol.
Volume11
DOIs
Publication statusPublished - 2020

Fingerprint Dive into the research topics of 'Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient'. Together they form a unique fingerprint.

Cite this